Zacks Research Has Negative Outlook for Teleflex Q2 Earnings

Teleflex Incorporated (NYSE:TFX - Free Report) - Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for Teleflex in a report released on Tuesday, June 24th. Zacks Research analyst R. Department now anticipates that the medical technology company will earn $3.91 per share for the quarter, down from their previous estimate of $3.93. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's FY2027 earnings at $15.09 EPS.

A number of other equities analysts also recently weighed in on the stock. Royal Bank Of Canada cut their price target on shares of Teleflex from $150.00 to $145.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Mizuho set a $155.00 target price on Teleflex in a research report on Wednesday, April 16th. Morgan Stanley dropped their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a report on Monday, May 5th. Truist Financial reduced their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research report on Monday, May 5th. Finally, Wall Street Zen lowered shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Sunday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $164.63.

Teleflex Trading Down 1.1%

TFX stock traded down $1.26 during midday trading on Friday, hitting $118.21. The stock had a trading volume of 595,878 shares, compared to its average volume of 856,188. The firm has a market cap of $5.22 billion, a PE ratio of 37.29, a price-to-earnings-growth ratio of 1.87 and a beta of 1.10. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.28 and a quick ratio of 1.32. Teleflex has a 12-month low of $115.94 and a 12-month high of $249.90. The company's 50-day moving average price is $124.41 and its 200 day moving average price is $147.33.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.03. The firm had revenue of $700.67 million during the quarter, compared to the consensus estimate of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. Teleflex's quarterly revenue was down 5.0% on a year-over-year basis. During the same period last year, the business posted $3.21 EPS.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $1.36 annualized dividend and a yield of 1.15%. Teleflex's payout ratio is presently 42.90%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. CX Institutional acquired a new position in Teleflex in the 1st quarter worth approximately $105,000. QRG Capital Management Inc. lifted its holdings in shares of Teleflex by 35.9% in the first quarter. QRG Capital Management Inc. now owns 2,959 shares of the medical technology company's stock valued at $409,000 after purchasing an additional 781 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Teleflex in the fourth quarter worth $10,342,000. IFP Advisors Inc grew its holdings in shares of Teleflex by 238.5% during the fourth quarter. IFP Advisors Inc now owns 308 shares of the medical technology company's stock valued at $55,000 after buying an additional 217 shares in the last quarter. Finally, UMB Bank n.a. raised its position in Teleflex by 3,763.6% during the first quarter. UMB Bank n.a. now owns 425 shares of the medical technology company's stock valued at $59,000 after buying an additional 414 shares during the period. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.